Literature DB >> 582790

Kinetic metabolism of vinpocetine in the rat.

L Vereczkey, Z Szentirmay, L Szporny.   

Abstract

The pharmacokinetics of vinpocetine (Cavinton), a new potent vasodilator, and of its main metabolite have been studied in rats by specific extraction and radio thin-layer chromatography following i.v. and p.o. administration. The drug is rapidly eliminated, its half-life was found to be 125 min. The apparent volume of distribution was 3.8 l/kg and the clearance rate 33 ml/min/kg. From the equation describing the concentration-time curve a two-compartement open model was computed. Bioavailability of vinpocetine after p.o. administration was about 50%. The main metabolite, free apovincaminic acid, is formed very rapidly in rats and is eliminated from plasma with a half-life of 360 min.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 582790

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  4 in total

1.  Embryo-fetal development studies with the dietary supplement vinpocetine in the rat and rabbit.

Authors:  Natasha Catlin; Suramya Waidyanatha; Eve Mylchreest; Lutfiya Miller-Pinsler; Helen Cunny; Paul Foster; Vicki Sutherland; Barry McIntyre
Journal:  Birth Defects Res       Date:  2018-02-19       Impact factor: 2.344

Review 2.  Pharmacokinetics and metabolism of vincamine and related compounds.

Authors:  L Vereczkey
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Apr-Jun       Impact factor: 2.441

3.  Systemic exposure of vinpocetine in pregnant Sprague Dawley rats following repeated oral exposure: An investigation of fetal transfer.

Authors:  Suramya Waidyanatha; Heather Toy; Natalie South; Seth Gibbs; Esra Mutlu; Brian Burback; Barry S McIntyre; Natasha Catlin
Journal:  Toxicol Appl Pharmacol       Date:  2017-11-15       Impact factor: 4.219

4.  Personalized medicine: Vinpocetine to reverse effects of GABRB3 mutation.

Authors:  Santoshi Billakota; J Michael Andresen; Bryant C Gay; Gregory R Stewart; Nikolai B Fedorov; Aaron C Gerlach; Orrin Devinsky
Journal:  Epilepsia       Date:  2019-11-22       Impact factor: 5.864

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.